Product name as reported
Makena: adverse event reports filed with FDA
22,669 reports list it as a suspect or interacting product, 2011–2024.
- 22,669
- reports as suspect product
- 0.1% of all reports · about 1,495 a year
- 0
- reports, 12 months to June 2026
- 2 in the 12 months before
- 49.1%
- marked serious by the reporter
- 57.4% across all reports
- 5.4%
- record death among outcomes, as reported
- 1,216 reports · not verified by FDA
22,669 adverse event reports received by FDA list the product name "Makena" as reporters wrote it as a suspect or interacting product, from May 2011 to November 2024. A further 19 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, against 2 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 1,495 reports a year and 0.1% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded premature delivery (19.1%), premature baby (17.5%) and injection site pain (11.4%). A report can list several reactions, so shares add to more than 100%; 561 different terms appear across these reports. Premature delivery is recorded in 19.1% of these reports, against 0.1% of all reports in the database.
49.1% of the reports are marked serious by the reporter; 5.4% record death among the outcomes and 27.7% record hospitalisation, as reported. 38.4% of the reports came from consumers, and the largest patient age group is 18 to 44 (45.7%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Makena reports recording the termall reports in the database
- Premature delivery19.1%4,339
- Premature babya baby born early17.5%3,976
- Injection site painpain where the injection was given11.4%2,578
- Injection site pruritusitching where the injection was given8.1%1,842
- Product dose omission issuea dose was missed7.3%1,663
- Inappropriate schedule of product administrationthe product was taken at the wrong times5.1%1,162
- Product administration errora mistake in giving the product4.3%969
- Injection site swellingswelling where the injection was given4.1%919
- Injection site mass3.6%822
- Injection site erythemaredness where the injection was given3.3%739
- Premature labour3.1%697
- Preterm premature rupture of membranes3.1%692
- Uterine contractions during pregnancy3%686
- Product dose omissiona dose was missed2.7%608
- Stillbirth2.5%563
- Pruritusitching2.4%541
- Pain in extremitypain in an arm or leg2.4%536
- Nauseafeeling sick2.2%498
- Headachehead pain2.1%481
- Abortion spontaneousmiscarriage2.1%480
- Therapy cessation2.1%477
- Injection site nodule1.9%422
- Off label useused for a purpose or in a way not on the label1.8%406
- Painpain, site not specified1.7%388
- Injection site rash1.7%384
- Dizzinesslight-headedness or unsteadiness1.5%333
- Injection site bruisingbruising where the injection was given1.5%330
- Peripheral swellingswelling of the arms or legs1.4%309
- Injection site warmth1.3%286
Top 30 of 561 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Premature delivery | 12,529 | 55.3% |
| Foetal exposure during pregnancy | 3,994 | 17.6% |
| Exposure during pregnancy | 934 | 4.1% |
| Premature labour | 677 | 3% |
| Pregnancy | 154 | 0.7% |
| Maternal exposure during pregnancy | 45 | 0.2% |
The indication field is filled in by the reporter and is often blank; shares are of all 22,669 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Makena reports |
|---|---|---|
| Aspirin | 157 | 0.7% |
| Iron | 126 | 0.6% |
| Zofran | 122 | 0.5% |
| Ferrous sulfate | 94 | 0.4% |
| Levothyroxine | 83 | 0.4% |
| Tylenol | 82 | 0.4% |
| Nifedipine | 80 | 0.4% |
| Folic acid | 79 | 0.3% |
| Metformin | 76 | 0.3% |
| Colace | 74 | 0.3% |
Other products listed in reports where Makena is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Makena | All reports |
|---|---|---|
| Reports as suspect product | 22,669 | 20,646,523 |
| Share of that pool | — | 0.1% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 49.1% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 54 | 91 |
| Hospitalisation recorded, per 1,000 reports | 277 | 213 |
| Consumer-filed share | 38.4% | 45.8% |
| Top term, share of reports | Premature delivery 19.1% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Makena reports
How many adverse event reports has FDA received for Makena?
22,669 reports list Makena as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 19 list it only as a concomitant medication.
What reactions are recorded in Makena reports?
premature delivery (19.1%), premature baby (17.5%), injection site pain (11.4%), injection site pruritus (8.1%) and product dose omission issue (7.3%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Makena was responsible.
How serious are the reports?
49.1% are marked serious by the reporter. Among the outcomes recorded, 5.4% of reports include death and 27.7% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (38.4%), not given (30.3%) and physician (20.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Makena rising?
0 reports in the 12 months to June 2026, against 2 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Makena was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Makena?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Makena as a suspect or interacting product; reports listing it only as a concomitant medication (19) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.